🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.

RecruitingNAAges 18 Years - 60 YearsAllSixth Affiliated Hospital, Sun Yat-sen University
NCT07081373 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Anal Fistula refers to an abnormal infectious fistula tract between the anorectum and the perianal skin. The prevalence of anal fistula is approximately 8.6 cases per 100,000 individuals. It can occur at any age but is relatively more common in individuals aged 20-40 years, with a higher incidence in males than females. Postoperative wound management is a critical component of the overall treatment for anal fistula patients. Regular postoperative wound care, such as dressing changes, can reduce recurrence rates, alleviate pain, and shorten hospitalization time. However, postoperative pain remains a major challenge in wound management following anal fistula surgery. This is largely attributed to inadequate current postoperative analgesic protocols. With ongoing advancements in local anesthetics, liposomal bupivacaine has been applied for postoperative analgesia. It offers higher bioavai

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosed with anal fistula and scheduled to undergo anal fistula surgery; * Aged between 18 and 60 years; * ASA (American Society of Anesthesiologists) physical status class I-II; * Patient provides written informed consent after understanding the study protocol. Exclusion Criteria: * Anal fistula caused by specific etiologies (e.g., tuberculosis); * Concurrent acute perianal skin infection; * Poorly controlled diabetes (HbA1c \>9%); * Chronic use of corticosteroids; * History of radiotherapy or chemotherapy within the past 2 weeks; * Pregnancy or lactation; * Hypersensitivity to local anesthetics or any component of the investigational drug; * History of substance abuse, illicit drug use, or alcohol abuse; * Use or planned use of non-opioid/opioid analgesics within 12 hours before/during surgery; * Concurrent treatment with anticonvulsants, MAO inhibitors, antidepressants, neuromuscular blockers, or anticholinergics within 2 weeks prior to surgery; * Severe hepatic/renal impairment, cardiopulmonary dysfunction, coagulation disorders, or comorbidities contraindicating surgery; * History of severe psychiatric disorders or cognitive impairment; * Sensory disorders (e.g., hyperalgesia) or preexisting pain interfering with postoperative pain assessment; * Contraindications to amide-type local anesthetics, opioids, or propofol; * Participation in investigational drug trials within 90 days prior to enrollment; * Other clinical/laboratory conditions deemed by investigators to preclude trial participation.
💊

What it tests

  • A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
📍

Where

1 site
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy